Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-18. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Analytes that are totally excluded, elute with the free volume outside around the particles (Vo), the total exclusion limit, while analytes that are completely delayed, elute with the solvent, marking the total permeation volume of the column, including also the solvent held inside the pores (Vi). The total volume can be considered by the following equation, where Vg is the volume of the polymer gel and Vt is the total volume:
=== Gelator === Gelators serve as stabilizers and thickeners, thickening the gel solution while simultaneously maintaining the gel's flexible nature. When dispersed through the solvent as a colloid, gelators offer a stable internal structure to the gel. Gelators are usually chosen based on their affinity for the solvent and the purpose of the gel. The nature of the gelators used determines the rigidity of the gel. There are many types of gelators, of which carbomers are more frequently used due to their ability to thicken gels across a wide range of pH. Gelators can be classified by polymer types, namely natural, semi-synthetic and synthetic polymers. Natural gelators include tragacanth, gelatin, collagen, and guar gum; semi-synthetic gelators include methylcellulose and other cellulose derivatives; while synthetic gelators include carbomers, polyvinyl alcohol, polyethylene and its copolymers.
Emus were used as a source of food by indigenous Australians and early European settlers. Emus are inquisitive birds and have been known to approach humans if they see unexpected movement of a limb or piece of clothing. In the wild, they may follow and observe people. Aboriginal Australians used a variety of techniques to catch the birds, including spearing them while they drank at waterholes, catching them in nets, and attracting them by imitating their calls or by arousing their curiosity with a ball of feathers and rags dangled from a tree. The pitchuri thornapple (Duboisia hopwoodii), or some similar poisonous plant, could be used to contaminate a waterhole, after which the disoriented emus were easy to catch. Another stratagem was for the hunter to use a skin as a disguise, and the birds could be lured into a camouflaged pit trap using rags or imitation calls. Aboriginal Australians only killed emus out of necessity, and frowned on anyone who hunted them for any other reason. Every part of the carcass had some use; the fat was harvested for its valuable, multiple-use oil, the bones were shaped into knives and tools, the feathers were used for body adornment and the tendons substituted for string. The early European settlers killed emus to provide food and used their fat for fuelling lamps. They also tried to prevent them from interfering with farming or invading settlements in search of water during drought. An extreme example of this was the Emu War in Western Australia in 1932.
The three substrates of this enzyme are 4-hydroxybenzaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are 4-hydroxybenzoic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3-hydroxybenzaldehyde:NAD+ oxidoreductase. This enzyme is also called p-hydroxybenzaldehyde dehydrogenase. This enzyme participates in toluene and xylene degradation in bacteria. It is also found in carrots (Daucus carota).
According to the Pew Research Center, 99.8% of Somalia's population is Muslim. The majority belong to the Sunni branch of Islam and the Shafi'i school of Islamic jurisprudence. Sufism, the mystical dimension of Islam, is well-established, with many congregations of various Sufi orders. It is the state religion. Christianity has around 1,000 adherents, less than 0.1% of the 2010 population. There were no Christians during early colonisation, although 100–200 followers came from the Catholic missions in British Somaliland, with no Catholic missions in Italian Somaliland. According to the Pew Research Center, less than 0.1% of Somalia's population, mainly Bantus, were adherents of folk religions.
Sources: en.wikipedia.org
=== Treatment === Due to their agitated behavior and confused mental state, people with acute Datura poisoning or intoxication are typically hospitalized. Gastric lavage and the administration of activated charcoal can be used to reduce the stomach's absorption of the ingested material, and the drug physostigmine is used to reverse the effect of the poisons. Benzodiazepines can be given to calm the patient's agitation, and supportive care with oxygen, hydration and symptomatic treatment is often provided. Observation of the patient is indicated until the symptoms resolve, usually from 24 to 36 hours after ingestion of the Datura.
== Indications == The decision to initiate dialysis or hemofiltration in patients with kidney failure depends on several factors. These can be divided into acute or chronic indications. Depression and kidney failure symptoms can be similar to each other. It is important that there is open communication between a dialysis team and the patient. Open communication will allow giving a better quality of life. Knowing the patients' needs will allow the dialysis team to provide more options like: changes in dialysis type like home dialysis for patients to be able to be more active or changes in eating habits to avoid unnecessary waste products.
== Life == Patton was born in Ebenezer, New York, to George Patton and Ina Neher Patton. He graduated from Radnor High School in Wayne, Pennsylvania, in 1938 and received his Bachelor of Science degree from Penn State University in 1943. He married Colleen Lavelle in 1945, to whose support in their 71-year marriage he often said he owed his success. They had seven children, four sons and three daughters. After serving as an ensign in the U.S. Navy during World War II, he pursued graduate work at Ohio State University, receiving his master's degree in 1947 and his Doctor of Philosophy in 1948, working under the direction of Donald V. Josephson. Their collaboration continued at Penn State, where both returned in 1948, Josephson as head of the Department of Dairy Husbandry and Patton as assistant professor. In 1966 Patton became the College of Agriculture's first Evan Pugh Professor. While at Penn State, Patton served as a consultant to The Borden Company (1952–72), the U. S. Department of Agriculture (1958≠61) and International Flavors and Fragrances, Inc. (1965–75), where his work resulted in three patents. Patton's collaboration with Andrew Benson, with whom he shared a common interest in the structure and function of the cell membrane, motivated his move to UCSD after his retirement from Penn State in 1980.
== Honors and awards == Bumpus has received numerous recognitions from the United States government for her work. In 2016, President Obama awarded her a Presidential Early Career Award for Scientists and Engineers, "the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their independent research careers". She delivered the National Institute of General Medical Sciences (NIGMS) Director's Early-Career Investigator Lecture in 2017, and was the Congressional Biomedical Research Caucus's invited speaker in March 2018, lecturing about informing consumers about drug metabolism. Bumpus became a fellow of the American Association for the Advancement of Science, in its Section on Pharmaceutical Sciences, in 2021. In 2022, she was elected to the National Academy of Medicine. Additional awards she has received include:
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.